Conservative surgery vs hysterectomy for placenta accreta spectrum disorders: a

systematic review and meta-analysis

Running title: Conservative surgery for placenta accreta spectrum disorders: a

systematic review

Gabriel Moreira Lino[1], Pauliana Valéria Machado Galvão[2], George Alessandro

Maranhão Conrado[1]

[1]University of Pernambuco, Serra Talhada, Brazil

[2]Faculty of Medical Sciences, University of Pernambuco, Recife, Brazil

Corresponding author: **Pauliana Valéria Machado Galvão**

Address: R. Arnóbio Marquês, 310 - Santo Amaro, Recife - PE, 50100-130

Telephone number: +55 81 996604662

Email address: pauliana.galvao@upe.br

ABSTRACT

Aim

Resection and reconstruction of the uterus may be an alternative to hysterectomy in placenta accreta spectrum disorders. We aimed to review whether surgical and maternal outcomes were comparable between these techniques.

Methods

Medline, Embase, and the Cochrane Library databases were searched until 1 January 2025. Randomized controlled trials (RCT) and nonrandomized studies (NRSI) comparing conservative surgery, involving resection and reconstruction of the myometrium without placental removal, to hysterectomy in patients with placenta accreta, increta, or percreta. The risk of bias was assessed with ROB-2 or ROBINS-I, and the quality of evidence with GRADE. The main analysis only included studies without a high risk of bias.

Results

We included one RCT and eleven nonrandomized studies (1586 women). Compared to hysterectomy, conservative surgery may result in similar intraoperative blood loss (MD -320.89 mL, 95% CI -574.95 to -66.82; 1 RCT and 3 NRSI, 637 women; $I^2 = 14\%$; low-certainty evidence), transfused packs of red blood cells (MD -0.70 packs, 95% CI -1.28 to -0.12; 1 RCT and 4 NRSI, 649 women; $I^2 = 0\%$; low-certainty evidence), and no difference in the risk of bladder injury (RR 0.36, 95% CI 0.12 to 1.07; 1 RCT and 4 NRSI, 649 women; $I^2 = 0\%$; low-certainty evidence).

Conclusions

On the basis of low evidence, conservative surgery did not increase the risk of clinically important harm compared to hysterectomy, with the benefit of uterus

preservation. Further RCTs are needed to reach definitive conclusions about potential

benefits. To improve the quality of evidence from low to moderate, a trial with an

additional 181 participants in the conservative surgery arm would be necessary to avoid

downgrading for imprecision.

Keywords: Placenta accreta. Surgery. Fertility. One-step surgery. Triple-P procedure.

Conservative management.

Registration: PROSPERO CRD42024601117.

INTRODUCTION

Until recently, hysterectomy was virtually the only management option for

placenta accreta spectrum disorder (PAS). However, as the prevalence of PAS has

increased to affect approximately 1 in every 313 women undergoing cesarean section, the

growing number of women wishing to preserve fertility has prompted investigation into

alternative strategies for uterine preservation[1]. Currently, leaving the placenta in situ is

one of the most utilized alternatives to hysterectomy, although it requires high-resource

settings and continuous long-term monitoring[2,3]. In this context, uterus-preserving

surgery (also referred to as one-step surgery, triple P procedure, or MOSCUS, according

to variations in the technique proposed by individual authors) has been developed to

provide immediate surgical resolution of PAS during cesarean delivery[4].

This technique involves removing the invaded myometrium and reconstructing

the uterine wall, with or without preventive surgical devascularization[2,4]. However, there

is still uncertainty regarding its efficacy and safety. Therefore, this review aims to

summarize the available evidence on this conservative surgical technique, comparing it

to hysterectomy in patients diagnosed with PAS who wish to preserve fertility.

METHODS

Protocol and registration

We registered this systematic review prospectively in the PROSPERO database,

identifier CRD42024601117.

Criteria for considering studies for this review

We considered randomized controlled trials (RCT) and nonrandomized studies of

interventions comparing conservative surgery to hysterectomy in patients with placenta

accreta, increta, or percreta. To be included, the surgical technique must have involved

resection of abnormally invasive placenta and myometrium and reconstruction of the

uterine wall. Therefore, we excluded studies that provided fertility preservation by

manual removal of the placenta followed by vascular control procedures, such as uterine

compressive sutures, tourniquets, and uterine devascularization.

The following critical outcomes were considered:

104   1. Intraoperative blood loss;

105   2. Number of transfused packs of red blood cells or women needing

106   transfusion;

107   3. Intraoperative visceral organ injury (bladder injury, bowel injury, ureter

108   injury, and vascular injury)

109   4. Reoperation;

110   5. Long-term complications of surgery (fistula, premature ovarian

111   insufficiency, urinary dysfunction, dysmenorrhea);

112   The secondary outcomes of the review were:

113   1. Duration of surgery;

114   2. Duration of hospital stay;

115   3. Admission to intensive care unit;

116   4. Postoperative infection.

Studies had to report at least one of the primary outcomes to be eligible for the

review.

Search methods for identification of studies

We searched for published studies up to January 2025, on Medline, Embase, and

the Cochrane Library using the terms: (one step conservative surgery OR uterine

conservative-resective surgery OR uterus resection OR uterine resective surgery OR

uterine conservative surgery OR uterus conservation surgery OR uterine preserving

surgery OR fertility sparing surgery OR fertility preserving surgery OR triple p procedure

OR triple p) and (placenta accreta spectrum OR placenta increta OR placenta percreta OR

abnormally invasive placenta OR morbidly adherent placenta). There were no language

restrictions.

Data collection and analysis

Two authors independently screened the title and abstract of the identified records.

If one of the authors considered the record eligible, both assessed the full text.

Subsequently, the authors selected and extracted information about study characteristics

to a previously cross-validated file.

Risk of bias assessment in included studies

Two authors used the Cochrane risk-of-bias tool for randomized trials (RoB 2),

version of August 2019, to assess the risk of bias/quality of the included randomized

trials[5]. The ROBINS-I V2 tool, 2024, was used instead for nonrandomized studies of

interventions[6]. We evaluated the overall risk of bias in each study based on three primary

outcomes (blood loss, transfusion, and intraoperative visceral organ injury). For the

assessment of the risk of bias in nonrandomized studies, the intention-to-treat analysis

section was considered. Dropouts, group conversions, or loss to follow-up below 5% were

judged as low risk of bias. Additionally, when more than 50% of the weight of the studies

contributing to an estimate was from studies at high risk of bias, the overall certainty of

evidence was downgraded.

Synthesis methods

We used an inverse-variance random effects model, reporting dichotomous data

as Relative Risk (RR) with 95% Confidence intervals (CI) and continuous outcomes as

mean differences (MD) and 95% CI. Statistical heterogeneity was assessed by calculating

tau (DerSimonian-Laird estimator and Jackson method for confidence interval of tau^2),

I^2, and Cochran's Q; I^2 higher than 50% was considered a significant indicator of

heterogeneity. We investigated publication bias with funnel plots and Egger's test.

Studies that reported medians and interquartile range were transformed using an

internal function of the meta package, following what was described by Luo and

collaborators[7]. We stratified our analyses based on the risk of bias (high and not high risk

of bias). Primary results in every section only included studies with randomized design

or that were not at high risk of bias. Subsequent analyses reported the estimated effect

including the remaining studies, except when the results of both analyses were uncertain,

making it unnecessary to report them separately.

Analyses were conducted in R, with the packages meta and metafor[8,9].

Certainty of the evidence assessment

The overall certainty of the evidence for each outcome was assessed by one

reviewer using the Grading of Recommendations, Assessment, Development and

Evaluation (GRADE) handbook[10]. The quality of the evidence was summarized in a

Summary of Findings table generated in GRADEpro GDT. For the evaluation of

imprecision, the update provided in 2022 was followed[11]. The Review Information Size

was determined using conventional power analysis ($\alpha = 0.05$; $\beta = 0.2$), taking into account

the range of standard deviations from randomized controlled trials and medium to low

risk of bias studies.

RESULTS

Results of the search

We initially identified 640 records in our search. Of these, 106 were deemed

potentially eligible, and 12 (only one RCT) were ultimately included in the review. The

primary reasons for exclusion were inadequate surgical techniques (manual placental

removal or failure to report surgical methods), poor study design (such as case series,

reports, reviews, editorials, and letters), absence of relevant outcome data specified in the

review protocol, and not comparing conservative surgery to hysterectomy (such as

comparing to manual removal of the placenta)(Figure 1).

Figure 1 Prisma 2020 flow diagram of study selection

Included studies

Table 1 summarizes the characteristics of the included studies. One RCT and eleven non-randomized studies were included, four of which had prospective designs. Moreover, some studies reported the PAS FIGO clinical grading[12], with patients of every grade in both arms. The average maternal age ranged from 30 to 37 years, with most women having had one or two previous cesarean sections.

Preventive vascular interventions before myometrial resection were utilized in three of the included studies. Further descriptions of methods, eligibility criteria, and participants are available in Supplementary Table S1. In general, the most common eligibility criteria for uterine conservative surgery were: (1) at least 2 cm of healthy myometrium in the anterior uterine wall, (2) more than 50% of the uterine circumference

without PAS involvement, and (3) the ability to safely dissect the bladder from the uterus.

Most studies followed the surgical technique described as one-step surgery[4].

Risk of bias of included studies

An overview of the risk of bias is provided in Table 1 and the detailed description

is presented in Table S2. The included RCT was classified as having a moderate risk of

bias due to the lack of blinding and important patient crossover/drop-out. Nearly all non-

randomized studies were considered at high risk of bias, as the selection of patients for

surgery relied primarily on intraoperative assessments based on the topography of the

invasive placenta. Additionally, few studies reported potential confounding variables or

adjusted their analyses as necessary.

Table 1 – Summary of characteristics of included studies

Author (Year)	Country	Study design	Sample size (CS; HT)	PAS FIGO grading (n)		Maternal age (y)		Previous cesarean deliveries (n)		Preventive vascular intervention	Risk of bias
				CS	HT	CS	HT	CS	HT		
Nieto-Calvache 2024[13]	Multicenter	RCT, not blinded	60 (29;31)	Grade 1 2 Grade 2 18 Grade 3A 3 Grade 3B-C 4	1 20 0 3	33.45±4.56	33.13 ±4.26	1: 14 2: 13	18 13	No	Moderate risk
Nieto-Calvache 2023[14]	Multicenter	NRSI, prospective design	75 (64;11)	-	-	33 (26−38)	31 (29−37)	-	-	No	Moderate risk
Paping 2024[15]	Multicenter	NRSI, retrospective design, prospectively-collected data	224 (38;186)	Grade 1 10 Grade 2 13 Grade 3A 14 Grade 3B-C 1	21 46 60 59	34 (30–37)	35 (31–39)	2 (1–3)	2 (1–2)	No	Moderate risk

Abouda 2024[16]	Single center	NRSI, prospective design	12 (6;6)	-	-	37.17±2.93	33.67±3.07	4±0.89	2.83±0.98	No	Moderate risk
van Beekhuizen 2021[17]	Multicenter	NRSI, retrospective design, prospectively collected data	278 (26;252)	Grade 1 3 / Grade 2 2 / Grade 3A 18 / Grade 3B-C 3	31 / 52 / 102 / 66	-	-	-	-	No	Moderate risk
Vuong 2024[18]	Single center	NRSI, retrospective design	296 (217;79)			33.17 ± 4.77	33.68 ± 4.94	1: 125 2: 73	36 36	No	High risk
Aryananda 2023[19]	Single center	NRSI, retrospective design	126 (91;35)	Grade 1 16 / Grade 2 54 / Grade 3A 15 / Grade 3B-C 6	0 / 7 / 10 / 18	33 (22–46)	33 (22–42)	2 (1–3)	2 (1–3)	No	High risk

Aryananda 2022[20]	Single center	NRSI, retrospective design	234 (200;34)	-	-	33 (19–44)	35 (26–41)	1: 147 2: 42	1: 20 2: 13	Yes: internal iliac artery ligation	High risk
Jafari 2022[21]	Single center	NRSI, retrospective design	68 (44;24)	-	-	33.23 ± 4.72	32.54 ± 5.69	-	-	No	High risk
Durukan 2021[22]	Single center	NRSI, retrospective design	65 (23;42)	-	-	33.1 ± 5.4	34.1 ± 5.4	2.0 ± 1.1	2.1 ± 0.9	No	High risk
Üstünyurt 2020[23]	Single center	NRSI, retrospective design	97 (30;67)	-	-	31.1±5.4	33.2±4.7	-	-	Yes: Intrauterine balloon tamponade	High risk
Kilicci 2018[24]	Single center	NRSI, retrospective design	51 (22;29)	-	-	32.3 ±5.3	32.45± 4.7	1.6 ±0.9	1.8 ±0.6	No	High risk

RCT: randomized controlled trial; NRSI: nonrandomized study of intervention.

An investigation into publication bias revealed that retrospective studies, which

were at high risk of bias, generally reported higher mean differences with larger standard

errors compared to studies with moderate to low risk of bias (Figure S1). However,

Egger's Test did not detect significant publication bias affecting the analysis (p-value =

0.2041).

Synthesis of results

1.1 Intraoperative blood loss

Conservative surgery may result in similar intraoperative blood loss compared to

hysterectomy (MD -320.89 mL, 95% CI -574.95 to -66.82; 1 RCT and 3 NRSI, 637

women; I^2= 14%; low-certainty evidence). By including studies at high risk of bias, the

difference in blood loss is larger, but of lower certainty (MD -497.33 mL, 95% CI -755.37

to -226.17; 1 RCT and 7 NRSI; I^2= 73%; very low-certainty evidence)(Figure 2).

Figure 2 Comparison of uterine conservative surgery vs hysterectomy on intraoperative blood loss in women with placenta accreta spectrum disorders

1.2 Number of transfused packs of red blood cells (pRBCs) and number of women needing transfusion

The number of transfused pRBCs per patient may be similar in conservative surgery compared to hysterectomy (MD -0.70 packs, 95% CI -1.28 to -0.12; 1 RCT and 4 NRSI, 649 women; I^2= 0%; low-certainty evidence). We are very uncertain that this benefit could be slightly larger (MD -1.15 packs, 95% CI -1.64 to -0.65; 1 RCT and 9 NRSI; I^2= 20%; very low-certainty evidence)(Figure 3). Moreover, there may be no difference in the number of patients needing blood transfusion (RR 0.87, 95% CI 0.67 to 1.13; 1 RCT and 1 NRSI, 135 women; I^2= 0%; low-certainty evidence) or fewer women

will require transfusion (RR 0.82, 95% CI 0.74 to 0.91; 1 RCT and 4 NRSI; I^2= 0%; very

low-certainty evidence).

Figure 3 Comparison of uterine conservative surgery vs hysterectomy on the number of

transfused pRBCs per patient in women with placenta accreta spectrum disorders

1.3 Intraoperative visceral organ injury

Risk of bladder injury may be similar (RR 0.36, 95% CI 0.12 to 1.07; 1 RCT and

4 NRSI, 649 women; I^2= 0%; low-certainty evidence) or there is a lower risk of bladder

injury (RR 0.32, 95% CI 0.19 to 0.54; 1 RCT and 6 NRSI; I^2= 0%; very low-certainty

evidence)(Figure 4). In the two studies that investigated ureter injuries, no cases were

present in either arm (2 NRSI, 87 women; very low-certainty evidence). No cases of

bowel injury were reported with conservative surgery and seven were reported with

hysterectomy (RR 0.17, 95% CI 0.02 to 1.65; 3 NRSI; $I^2 = 17\%$; very low-certainty

evidence).

Figure 4 Comparison of uterine conservative surgery vs hysterectomy on bladder injury

in women with placenta accreta spectrum disorders

1.4 Reoperation

293   The risk of surgical reintervention was not different (RR 0.50, 95% CI 0.07 to

294 3.51; 1 RCT and 3 NRSI; $I^2= 0\%$; very low-certainty evidence)(RR 0.45, 95% CI 0.05 to

295 3.23; 1 RCT and 5 NRSI; $I^2= 0\%$; very low-certainty evidence).

297 *1.5 Long-term complications of surgery*

298   There is no indication that the type of surgery influences the formation of

299 vesicovaginal fistula (RR 1.40, 95% CI 0.16 to 12.08; 1 RCT and 1 NRSI, 294 women;

300 $I^2= 0\%$; very low-certainty evidence).

302 *1.6 Duration of surgery*

303   Duration of surgery may be similar (MD -36.31 minutes, 95% CI -73.06 to 0.43;

304 1 RCT and 2 NRSI, 147 women; $I^2= 54\%$; low-certainty evidence) or conservative

305 surgery could be shorter, however high heterogeneity limits the interpretation of this

306 analysis (MD -26.45 minutes, 95% CI -45.35 to -7.56; 1 RCT and 6 NRSI; $I^2= 89\%$; very

307 low-certainty evidence)(Figure 5).

Figure 5 Comparison of uterine conservative surgery vs hysterectomy on the duration

of surgery in women with placenta accreta spectrum disorders

1.7 Duration of hospital stay

There was little to no difference in the duration of hospital stay (MD -0.39 days,

95% CI -0.87 to 0.08; 1 RCT and 4 NRSI; I^2=33%; very low-certainty evidence). This

could be subjected to individual protocols in each hospital and not related to the surgeries

investigated.

1.7 Admission to the intensive care unit (ICU)

The risk of ICU admission may be similar (RR 1.11, 95% CI 0.83 to 1.47; 1 RCT

and 4 NRSI; $I^2 = 0\%$; very low-certainty evidence).

Certainty of evidence

The certainty of the evidence ranged from low to very low, according to the

GRADE assessment (Table 2). Whenever the analysis included nonrandomized studies,

the evidence was limited to low. If only trial data were included, the Review Information

Size (RIS) necessary to not downgrade for imprecision, for equally divided groups, would

be: 166 to 594 participants for pRBC, and 210 to 4908 participants for blood loss,

assuming moderate to small effects for the outcomes.

Table 2 – Summary of findings

Summary of Findings for conservative surgery Versus hysterectomy for surgical management of placenta accreta spectrum disorders							
Outcome and follow-up	Patients (studies), N	Relative effect (95% CI)	Absolute effects (95% CI)			Certainty	What happens
			hysterectomy	conservative surgery	Difference		
Estimated intraoperative blood loss	637 (1 RCT and 3 NRSI)	-	-	-	**-320.89** (-574.95 to -66.82)	⊕⊕◯◯ Low[a,b]	Conservative surgery may result in little to no difference in estimated intraoperative blood loss.
Transfused packs of RBCs	649 (1 RCT and 4 NRSI)	-	-	-	**-0.7** (-1.28 to -0.12)	⊕⊕◯◯ Low[a,b]	Conservative surgery may result in little to no difference in transfused pRBCs.

Summary of Findings for conservative surgery Versus hysterectomy for surgical management of placenta accreta spectrum disorders

Outcome and follow-up	Patients (studies), N	Relative effect (95% CI)	Absolute effects (95% CI)			Certainty	What happens
			hysterectomy	conservative surgery	Difference		
Need for transfusion	135 (1 RCT and 1 NRSI)	**RR = 0.87** (0.67 to 1.13)	667 per 1.000	**580 per 1.000** (447 to 753)	**87 fewer per 1.000** (from 220 fewer to 87 more)	⊕⊕◯◯ Low[a,b]	Conservative surgery may result in little to no difference in need for transfusion.
Bladder injury	649 (1 RCT and 4 NRSI)	**RR = 0.36** (0.12 to 1.07)	132 per 1.000	**47 per 1.000** (16 to 141)	**84 fewer per 1.000** (from 116 fewer to 9 more)	⊕⊕◯◯ Low[a,b]	Conservative surgery may result in little to no difference in bladder injury.
Reoperation	425 (1 RCT and 4 NRSI)	**RR = 0.50** (0.07 to 3.51)	70 per 1.000	**35 per 1.000** (5 to 246)	**35 fewer per 1.000** (from 65 fewer to 176 more)	⊕◯◯◯ Very low[a,c]	The evidence is very uncertain about the effect of conservative surgery on reoperation.
Vesicovaginal fistula	284 (2 non-randomised studies)	**RR = 1.40** (0.16 to 12.08)	14 per 1.000	**19 per 1.000** (2 to 167)	**6 more per 1.000** (from 12 fewer to 153 more)	⊕◯◯◯ Very low[a,c]	The evidence is very uncertain about the effect of conservative surgery on vesicovaginal fistula.
Duration of surgery	147 (1 RCT and 4 NRSI)	-	0	-	**-36.31** (-73.06 to 0.43)	⊕⊕◯◯ Low[a,b]	Conservative surgery may result in little to no difference in duration of surgery.

CI: confidence interval; **MD:** mean difference; **RR:** risk ratio

a. Moderate-risk nonrandomized studies included

b. 95% CI crosses trivial effect threshold

c. 95% CI crosses serious harm threshold

DISCUSSION

Summary of main results

Conservative surgery has the advantage of preserving the uterus with surgical

outcomes that appear to be similar to hysterectomy. The effect on reoperation, admission

to the intensive care unit, and vesicovaginal fistula, is uncertain, as the 95% CI included

substantial benefit and substantial harm. Notably, the risk of intraoperative visceral injury

and the number of transfused red blood cell packs may be lower or similar to

hysterectomy. Importantly, patients had to have a specific PAS topography to be eligible

for conservative surgery, with generally at least 2 cm of healthy myometrium on the

anterior uterine wall, >50% of the uterine circumference free of PAS, without

vesicouterine fibrosis, or extensive invasion of the lower anterior uterine wall. These

findings mainly concern, and validate, the one-step surgery technique.

Limitations of the evidence included in the review

The most important limitation of our study is the inclusion of nonrandomized

studies of interventions. Major limitations that future trials on PAS would face are the

low incidence of PAS, which requires longer recruitment and results in smaller samples,

the long-term follow-up needed to determine patient-centered outcomes, and the specific

placenta topography that limits the number of eligible women to be recruited.

Fundamentally, nonrandomized studies are better at evaluating potential harm than

potential benefit[25]. Combining RCT data with moderate-risk observational studies was

judged as necessary in our review once a review of randomized trials could not answer

the proposed comparisons, as we intended to provide reasonable point estimates for

minimal sample size calculations, and a safety overview. Therefore, we limited our

conclusions to evaluating harm rather than proving the superiority of conservative

surgery.

Inherent consequences of results drawn from these studies are uncontrolled

confounding and suboptimal outcome reporting. Even after excluding high-risk studies

from the main analysis, the confidence in the estimates provided was low. If only the data

of the randomized trial were analyzed, the small sample size and wide confidence

intervals would make it unreasonable to assume any given effect for conservative surgery.

Additionally, not all patients can be considered for conservative surgery, as there

are topographical constraints to this technique. Another limitation was the lack of patient-

driven outcomes in the included studies. However, it could be argued that uterus

preservation (with reasonable safety) would be the most prominent outcome for patients.

Agreements and disagreements with other studies or reviews

The success rate of conservative surgery in preserving fertility was reviewed

elsewhere, and hence, was not one of our outcomes of interest[26]. Notably, subsequent

pregnancy is possible, however, adverse maternal outcomes or recurrence of PAS was

reported in nearly 20% of patients, and hysterectomy was necessary for around 2% of all

women[26,27]. Such findings should be interpreted in the context of very low-certainty

evidence due to the limitations of these studies.

Our results add substantially to the initial assessment from FIGO in 2018, in which

it was suggested that leaving the placenta in situ was a valid management option for

women desiring to preserve fertility while conservative surgery remained unclear[2]. Here

we present both randomized and prospective nonrandomized data that suggest the safety

of the conservative surgery in some outcomes. Leaving the placenta in situ was recently

further validated by the PACCRETA study, a large nonrandomized, multicenter,

prospective, parallel-group study[28]. In theory, considering both nonsurgical and surgical

conservative management for PAS would be ideal for women desiring to preserve

fertility, as these approaches have different shortcomings and eligibility criteria.

Moreover, there are many variations of conservative surgery, which include

prophylactic balloon occlusion or major vascular intervention (such as the triple P

procedure)[29]. However, many of these studies did not compare their interventions to

hysterectomy and, therefore, were excluded from our review. The studies that were

eventually included were not randomized and almost all had a high risk of bias, making

it impossible to derive any conclusions about prophylactic vascular interventions. In

previous studies, conflicting meta-analyses and randomized controlled trial results

reported benefit or no effect of prophylactic balloon occlusion in women undergoing

hysterectomy for PAS[30,31]. The studies suggesting benefits were mostly nonrandomized,

and the trials had limited sample sizes; hence, this is an ongoing topic of discussion that

could be relevant for conservative surgical management of PAS.

Concerning intraoperative safety, the management of PAS requires careful

consideration due to the complexity of interventions and the potential for visceral organ

injuries. Urological complications occur in approximately 20% of all hysterectomies

performed in PAS cases[32]. Our review suggests with low certainty a potential lower risk

of bladder injury and no increased risk of ureteric injury. These findings could represent

a significant advancement and warrant further investigation in future trials.

Implications for practice

Conservative surgery in women diagnosed with placenta accreta spectrum

disorders, and with sufficiently healthy lower anterior uterine wall and uterine

circumference, may not lead to higher blood loss, number of packs of red blood cells

transfused, intraoperative visceral organ injury, and duration of surgery compared to

hysterectomy. Therefore, uterus preservation is possible without the risk of substantial

harm in critical outcomes likely increasing. This surgical procedure is not possible in all

women diagnosed with PAS, especially in the presence of vesicouterine fibrosis.

Implications for research

Further research should seek to increase the total sample size of randomized trials

comparing conservative surgery to hysterectomy in order to minimize imprecision on

confidence interval boundaries and review information size. Additionally, it would be

ideal to determine whether there are specific variations of conservative surgery, especially

involving prophylactic balloon occlusion, that result in better surgical outcomes. At

present, our results suggest that conservative management does not result in substantially

increased harm to women compared to hysterectomy, but more precise estimates would

allow the determination of possible benefits.

DECLARATIONS

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Availability of data and materials

The data can be shared upon request

Competing interests

The authors declare that they have no competing interests

Funding

No specific funding was available for the project

Acknowledgments

Not applicable.

REFERENCES

1. Matsuzaki S, Mandelbaum RS, Sangara RN, et al. Trends, characteristics, and outcomes of

placenta accreta spectrum: a national study in the United States. *Am J Obstet Gynecol*.

2021;225(5):534.e1-534.e38. doi:10.1016/j.ajog.2021.04.233

2. Sentilhes L, Kayem G, Chandraharan E, Palacios-Jaraquemada J, Jauniaux E, FIGO

Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus

guidelines on placenta accreta spectrum disorders: Conservative management. *Int J*

Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet. 2018;140(3):291-298.

doi:10.1002/ijgo.12410

3. Sentilhes L, Seco A, Azria E, et al. Conservative management or cesarean hysterectomy for

placenta accreta spectrum: the PACCRETA prospective study. *Am J Obstet Gynecol*.

2022;226(6):839.e1-839.e24. doi:10.1016/j.ajog.2021.12.013

4. Palacios Jaraquemada JM, Pesaresi M, Nassif JC, Hermosid S. Anterior placenta percreta:

surgical approach, hemostasis and uterine repair. *Acta Obstet Gynecol Scand*.

2004;83(8):738-744. doi:10.1111/j.0001-6349.2004.00517.x

5. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in

randomised trials. *BMJ*. 2019;366:l4898. doi:10.1136/bmj.l4898

6. Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in

non-randomised studies of interventions. *BMJ*. 2016;355:i4919. doi:10.1136/bmj.i4919

7. Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size,

median, mid-range, and/or mid-quartile range. *Stat Methods Med Res*. 2018;27(6):1785-

1805. doi:10.1177/0962280216669183

8. Viechtbauer W. Conducting meta-analyses in {R} with the {metafor} package. *J Stat Softw*.

2010;36(3).

9. Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical

tutorial. *Evid Based Ment Health*. 2019;22(4):153-160. doi:10.1136/ebmental-2019-300117

10. Schünemann H, Brożek J, Guyatt G, Oxman A, editor(s). Handbook for grading the quality

of evidence and the strength of recommendations using the GRADE approach (updated

October 2013). Published online 2013.

https://gdt.gradepro.org/app/handbook/handbook.html

11. Zeng L, Brignardello-Petersen R, Hultcrantz M, et al. GRADE Guidance 34: update on

rating imprecision using a minimally contextualized approach. *J Clin Epidemiol*.

2022;150:216-224. doi:10.1016/j.jclinepi.2022.07.014

12. Jauniaux E, Ayres-de-Campos D, Langhoff-Roos J, Fox KA, Collins S, FIGO Placenta

Accreta Diagnosis and Management Expert Consensus Panel. FIGO classification for the

clinical diagnosis of placenta accreta spectrum disorders. *Int J Gynaecol Obstet Off Organ*

Int Fed Gynaecol Obstet. 2019;146(1):20-24. doi:10.1002/ijgo.12761

13. Nieto-Calvache ÁJ, Aryananda RA, Palacios-Jaraquemada JM, et al. One-step conservative

surgery vs hysterectomy for placenta accreta spectrum: a feasibility randomized controlled

trial. *Am J Obstet Gynecol MFM*. 2024;6(6):101333. doi:10.1016/j.ajogmf.2024.101333

14. Nieto-Calvache AJ, Palacios-Jaraquemada JM, Aryananda R, et al. How to perform the

one-step conservative surgery for placenta accreta spectrum move by move. *Am J Obstet*

Gynecol MFM. 2023;5(2):100802. doi:10.1016/j.ajogmf.2022.100802

15. Paping A, Bluth A, Al Naimi A, et al. Opportunities for, and barriers to, uterus-preserving

surgical techniques for placenta accreta spectrum. *Acta Obstet Gynecol Scand*. Published

online May 2, 2024. doi:10.1111/aogs.14855

16. Abouda HS, Aloui H, Azouz E, et al. New surgical technique for managing placenta accreta

spectrum and pilot study of the "CMNT PAS" study. *AJOG Glob Rep*. 2025;5(1):100430.

doi:10.1016/j.xagr.2024.100430

17. van Beekhuizen HJ, Stefanovic V, Schwickert A, et al. A multicenter observational survey

of management strategies in 442 pregnancies with suspected placenta accreta spectrum.

Acta Obstet Gynecol Scand. 2021;100 Suppl 1(Suppl 1):12-20. doi:10.1111/aogs.14096

18. Vuong ADB, Pham TH, Pham XTT, et al. Modified one-step conservative uterine surgery

(MOSCUS) versus cesarean hysterectomy in the management of placenta accreta spectrum:

A single-center retrospective analysis based on 619 Vietnamese pregnant women. *Int J*

Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet. 2024;165(2):723-736.

doi:10.1002/ijgo.15220

19. Aryananda RA, Duvekot JJ, Van Beekhuizen HJ, Cininta NI, Ariani G, Dachlan EG.

Transabdominal and transvaginal ultrasound findings help to guide the clinical management

of placenta accreta spectrum cases. *Acta Obstet Gynecol Scand*. 2024;103(1):93-102.

doi:10.1111/aogs.14715

20. Aryananda RA, Aditiawarman A, Gumilar KE, et al. Uterine conservative-resective surgery

for selected placenta accreta spectrum cases: Surgical-vascular control methods. *Acta*

Obstet Gynecol Scand. 2022;101(6):639-648. doi:10.1111/aogs.14348

21. Mohammad Jafari R, Najafian M, Barati M, Saadati N, Jalili Z, Poolad A. Comparison of

uterine preservation versus hysterectomy in women with placenta accreta: A cross-sectional

study. *Int J Reprod Biomed*. 2022;20(9):739-744. doi:10.18502/ijrm.v20i9.12063

22. Durukan H, Durukan ÖB, Yazıcı FG. Placenta accreta spectrum disorder: a comparison

between fertility-sparing techniques and hysterectomy. *J Obstet Gynaecol J Inst Obstet*

Gynaecol. 2021;41(3):353-359. doi:10.1080/01443615.2020.1755629

23. Üstünyurt E. Local uterine resection with Bakri balloon placement in placenta accreta

spectrum disorders. *Turk J Obstet Gynecol*. 2020;17(2):108-114.

doi:10.4274/tjod.galenos.2020.82652

24. Kilicci C, Ozkaya E, Eser A, et al. Planned cesarean hysterectomy versus modified form of

segmental resection in patients with placenta percreta. *J Matern-Fetal Neonatal Med Off J*

Eur Assoc Perinat Med Fed Asia Ocean Perinat Soc Int Soc Perinat Obstet.

2018;31(22):2935-2940. doi:10.1080/14767058.2017.1359535

25. Reeves B, Deeks J, Higgins J, Shea B, Tugwell P, Wells G. Chapter 24: Including non-

randomized studies on intervention effects. Cochrane Handbook for Systematic Reviews of

Interventions version 6.4 (updated August 2023). Published online 2023. Accessed

December 26, 2023. https://training.cochrane.org/handbook/current/chapter-24

26. Javinani A, Qaderi S, Hessami K, et al. Delivery outcomes in the subsequent pregnancy

following the conservative management of placenta accreta spectrum disorder: a systematic

review and meta-analysis. *Am J Obstet Gynecol*. 2024;230(5):485-492.e7.

doi:10.1016/j.ajog.2023.10.047

27. Zhao H, Liu C, Fu H, Abeykoon SDI, Zhao X. Subsequent pregnancy outcomes and risk

factors following conservative treatment for placenta accreta spectrum: a retrospective

cohort study. *Am J Obstet Gynecol MFM*. 2023;5(12):101189.

doi:10.1016/j.ajogmf.2023.101189

28. Sentilhes L, Seco A, Azria E, et al. Conservative management or cesarean hysterectomy for

placenta accreta spectrum: the PACCRETA prospective study. *Am J Obstet Gynecol*.

2022;226(6):839.e1-839.e24. doi:10.1016/j.ajog.2021.12.013

29. Piñas-Carrillo A, Chandraharan E. Conservative surgical approach: The Triple P procedure.

Best Pract Res Clin Obstet Gynaecol. 2021;72:67-74. doi:10.1016/j.bpobgyn.2020.07.009

30. Bonsen LR, Sleijpen K, Hendriks J, et al. Prophylactic Radiologic Interventions for

Postpartum Hemorrhage Control in Women With Placenta Accreta Spectrum Disorder.

Obstet Gynecol. 2024;144(3):315-327. doi:10.1097/AOG.0000000000005662

31. Yu SCH, Cheng YKY, Tse WT, et al. Perioperative prophylactic internal iliac artery

balloon occlusion in the prevention of postpartum hemorrhage in placenta previa: a

randomized controlled trial. *Am J Obstet Gynecol*. 2020;223(1):117.e1-117.e13.

doi:10.1016/j.ajog.2020.01.024

32. Lucidi A, Jauniaux E, Hussein AM, et al. Urological complications in women undergoing

Cesarean section for placenta accreta spectrum disorders: systematic review and meta-

analysis. *Ultrasound Obstet Gynecol*. 2023;62(5):633-643. doi:10.1002/uog.26299

560   **Figure S1** Funnel plot of included studies reporting the outcome number of red blood

561   cell packages per group

562   **Table S1** Characteristics of included studies

563   **Table S2** Risk of bias of included studies

564